Pazopanib: therapeutic developments

被引：25

作者：

Limvorasak, Suwicha ^{[1
]}

Posadas, Edwin M. ^{[1
]}

机构：

[1] Univ Chicago, Dept Med Hematol & Oncol, Chicago, IL 60637 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2009年 / 10卷 / 18期

关键词：

ovarian cancer; pazopanib; renal cell carcinoma; soft tissue sarcoma; tyrosine kinase inhibitor; VEGFR; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; MULTIKINASE ANGIOGENESIS INHIBITOR; PHASE-II; FACTOR EXPRESSION; MULTIPLE-MYELOMA; CELL; VEGF; CANCER; SORAFENIB;

D O I：

10.1517/14656560903436493

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clinical development. Like other orally available VEGFR inhibitors, pazopanib is clinically efficacious and well tolerated. The recently reported Phase III clinical trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval. Given the growing number of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.

引用

页码：3091 / 3102

页数：12

共 76 条

[1]

ALTORKI N, 2008, J CLIN ONCOL S, V26

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], J CLIN ONCOL

[4]

ASPITIA AM, 2009, J CLIN ONCOL, V27, P11

[5] Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy [J].

Azad, Nilofer S. ;

Aragon-Ching, Jeanny B. ;

Dahut, William L. ;

Gutierrez, Martin ;

Figg, William D. ;

Jain, Lokesh ;

Steinberg, Seth M. ;

Turner, Maria L. ;

Kohn, Elise C. ;

Kong, Heidi H. .

CLINICAL CANCER RESEARCH, 2009, 15 (04) :1411-1416

[6] VEGF kinase inhibitors: how do they cause hypertension? [J].

Bhargava, Pankaj .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2009, 297 (01) :R1-R5

[7] A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185 [J].

Biagi, J. J. ;

Oza, A. M. ;

Grimshaw, R. ;

Ellard, S. L. ;

Lee, U. ;

Sederias, J. ;

Ivy, S. P. ;

Eisenhauer, E. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[8]

Bible KC, 2009, J CLIN ONCOL, V27

[9] Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents [J].

Bilodeau, MT ;

Fraley, ME ;

Hartman, GD .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) :737-745

[10]

Borgstrom P, 1996, CANCER RES, V56, P4032

← 1 2 3 4 5 6 7 8 →